Logo

FEMY

Femasys Inc.

FEMY

Femasys Inc. • NASDAQ
$1.01 ▲ 1.97% (+0.02)
Market Cap $29.74 M
52w High $1.80
52w Low $0.31
Dividend Yield 0%
P/E -1.46
Volume 549.89K
Outstanding Shares 29.45M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $729.394K ▲ $3.878M ▼ $-4.195M ▲ -575.11% ▲ $-0.1 ▲ $-3.452M ▲
Q2-2025 $409.268K ▲ $3.888M ▼ $-4.586M ▲ -1.121K% ▲ $-0.16 ▲ $-3.88M ▲
Q1-2025 $341.264K ▼ $5.685M ▲ $-5.897M ▼ -1.728K% ▼ $-0.23 ▼ $-5.225M ▼
Q4-2024 $581.576K ▲ $5.112M ▼ $-5.124M ▲ -881% ▲ $-0.22 ▲ $-4.455M ▲
Q3-2024 $554.908K $5.483M $-5.409M -974.731% $-0.24 $-4.779M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.569M ▲ $16.29M ▲ $11.734M ▼ $4.556M ▲
Q2-2025 $3.218M ▼ $13.78M ▲ $12.273M ▲ $1.507M ▼
Q1-2025 $3.82M ▲ $13.278M ▲ $11.281M ▲ $1.997M ▼
Q4-2024 $3.452M ▼ $12.445M ▼ $10.141M ▲ $2.304M ▼
Q3-2024 $7.611M $15.585M $9.615M $5.97M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.195M ▲ $-5.387M ▼ $-239.816K ▼ $6.978M ▲ $1.351M ▲ $-5.582M ▼
Q2-2025 $-4.586M ▲ $-4.353M ▲ $-96.962K ▼ $3.848M ▼ $-602.141K ▼ $-4.447M ▲
Q1-2025 $-5.897M ▼ $-4.765M ▲ $-96.605K ▲ $5.23M ▲ $368.447K ▲ $-4.862M ▲
Q4-2024 $-5.124M ▲ $-5.075M ▲ $-110.613K ▲ $1.026M ▲ $-4.159M ▲ $-5.185M ▲
Q3-2024 $-5.409M $-5.475M $-440.028K $0 $-5.915M $-5.915M

Five-Year Company Overview

Income Statement

Income Statement Femasys is still essentially a pre‑revenue company. Over the past several years it has not generated meaningful product sales, while consistently recording operating losses. These losses seem fairly stable in size year to year, which is typical of an early-stage medtech firm ramping R&D, clinical trials, and commercialization infrastructure without yet seeing material revenue. The pattern suggests the business is still in the build‑out and validation phase rather than in a mature, revenue-producing phase. Profitability appears a distant goal and will likely depend heavily on successful product adoption and regulatory milestones.

Balance Sheet

Balance Sheet The balance sheet looks light and fairly fragile. The company holds a small base of total assets and a modest cash balance relative to its ongoing costs. Debt has appeared on the balance sheet in recent years, and shareholder equity swung from negative to slightly positive, but remains thin. Overall, Femasys does not have a deep financial cushion; its ability to sustain operations and fund commercialization depends on continued access to outside capital and careful cost control. Any setbacks in trials or commercialization could strain this limited balance sheet capacity.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting spending on research, clinical trials, and early commercial efforts without offsetting revenue. Capital expenditures have been minimal, which fits a model focused more on product development and clinical work than on heavy manufacturing assets. Free cash flow has been negative for several years, so the company is reliant on financing rounds and other external funding to cover its cash burn. The key risk is how long its current resources and financing arrangements can support operations before it needs additional capital.

Competitive Edge

Competitive Edge Competitively, Femasys is carving out a focused niche in women’s health by emphasizing in‑office, minimally invasive procedures for infertility, permanent contraception, and cancer diagnostics. This approach can be attractive to patients, physicians, and payers because it aims to move procedures out of the operating room and into a lower‑cost, more convenient setting. The company’s patent portfolio, which covers multiple products and extends well into the future, provides a strong defensive moat against direct copycats. However, Femasys is still small and early compared with large, established players in fertility, contraception, and diagnostic tools. It must overcome physician habits, reimbursement hurdles, and competition from both traditional surgeries and other fertility and diagnostic approaches. Its competitive strength will ultimately depend on real‑world clinical outcomes, ease of use, safety profiles, and the company’s ability to educate and support healthcare providers.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Femasys’s story. The company has built a suite of differentiated products: FemaSeed and FemVue for infertility diagnosis and treatment, FemBloc for non‑surgical permanent contraception, and FemCerv for improved cervical sampling. All are aimed at solving long‑standing pain points in women’s health by making procedures simpler, safer, and more accessible in a doctor’s office. The intellectual property base is extensive, with many patents protecting key devices and methods into the next decade and beyond. Ongoing clinical trials, especially for FemBloc, are critical milestones. Regulatory progress in the U.S. and approvals in several international markets for some products are encouraging, but not yet fully de‑risking. Recent capital raises indicate a commitment to pushing these innovations toward full commercialization, while also highlighting continued dependence on the capital markets to finance R&D and launch activities. The main uncertainty is whether clinical results, regulatory reviews, and physician adoption will all align strongly enough to justify the investment made in this pipeline.

Summary

Femasys is a young, innovation‑driven medical device company in women’s health that is still in the pre‑revenue or very early revenue phase. Its financial profile is characterized by consistent operating losses, a light balance sheet, and ongoing negative cash flow, pointing to continued reliance on external funding. Strategically, the company’s value proposition centers on in‑office, minimally invasive alternatives for fertility treatment, permanent contraception, and cancer diagnostics, backed by a substantial patent estate and active clinical programs. This creates meaningful long‑term potential but also considerable execution and funding risk. The future trajectory will largely depend on the success of pivotal trials (especially for FemBloc), regulatory outcomes, physician and patient adoption of its products, and Femasys’s ability to convert its strong innovation and IP position into sustainable, growing revenue streams.

NEWS

November 25, 2025 · 9:15 AM UTC

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Read more

November 3, 2025 · 8:30 AM UTC

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Read more

October 16, 2025 · 9:00 AM UTC

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Read more

September 11, 2025 · 9:00 AM UTC

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Read more